News List
Gilead’s Investigational Lenacapavir Demonstrates Sustained Long-Acting Efficacy Through Week 26 in Data Presented at CROI
2021-03-15
Gilead Sciences, Inc. (Nasdaq: GILD) today presented additional results from the Phase 2/3 CAPELLA t
BeiGene Announces EMA Acceptance of its Marketing Authorization Application for BRUKINSA® (Zanubrutinib) for the Treatment of Patients with WM
2021-02-25
On June 18, 2020, BeiGene, Ltd. (“BeiGene” or the “Company”), a commercial-stage biotechnology compa
VISEN Pharmaceutical's TransCon C-type natriuretic peptide Phase II clinical trial application approved in China
2021-02-09
January 7, VISEN Pharmaceuticals announced that it had submitted TransCon CNP (TransCon C-type natri
Progress in the development of new and efficient diabetes treatment drugs
2021-01-20
Recently, Wang Junfeng's research team from Hefei Institute of Material Science, Chinese Academy
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA
2020-12-22
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S.
Merck's new HIV drug Pedro (Doravirin) was approved in China
2020-12-09
Merck announced recentlythat its new HIV drug Pedro (doravirin tablets) has been officially approved
FDA Grants Priority Review and EMA Accepts Regulatory Submission for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe Atopic Dermatitis
2020-11-03
Pfizer announced that the U.S. Food and Drug Administration (FDA) accepted for filing and granted Pr
ViiV Healthcare receives positive CHMP opinion for long-acting regimen for the treatment of HIV
2020-10-18
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shion
European Commission Grants Marketing Authorization for Jyseleca® ▼ (Filgotinib) for the Treatment of Adults With Moderate to Severe Active Rheumatoid Arthritis
2020-09-28
Gilead Sciences and Galapagos NV today announced that the European Commission (EC) has granted marke
Janssen Announces European Commission Decision for Expanded Use of IMBRUVICA® (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukaemia (CLL)
2020-09-10
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Comm